Last updated: September 2, 2026
Dichlorphenamide, marketed in the United States as Keveyis by Xeris Biopharma, is a high-priced orphan drug for primary periodic paralysis. Its commercial profile is shaped by a small diagnosed population, chronic treatment, limited therapeutic substitution, and orphan-drug market exclusivity rather than by broad prescription volume. Xeris has not separately disclosed complete Keveyis revenue and profitability in all reporting periods, limiting product-level valuation precision. The drug remains commercially defensible, but future growth depends on diagnosis expansion, payer access, adherence, and protection against generic entry.
What is dichlorphenamide and which patients does it treat?
Dichlorphenamide is an oral carbonic anhydrase inhibitor approved for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants in adults and adolescents aged 12 years and older. The product is supplied as 50 mg tablets and is administered once or twice daily depending on clinical response and tolerability (U.S. Food and Drug Administration [FDA], 2023).
Primary periodic paralysis is a rare inherited neuromuscular disorder characterized by episodic muscle weakness. Attacks can be triggered by rest after exercise, carbohydrate intake, stress, or changes in serum potassium. The disease is associated with mutations affecting skeletal-muscle ion channels, including CACNA1S and SCN4A.
Dichlorphenamide reduces attack frequency in both hyperkalemic and hypokalemic forms. Its differentiated value is clinical rather than technological: it is one of the few FDA-approved treatments specifically indicated for primary periodic paralysis.
How large is the dichlorphenamide addressable market?
The addressable market is small in patient count but potentially substantial in annual revenue per treated patient. Periodic paralysis prevalence estimates vary by subtype and geography, and underdiagnosis is common because attacks may be mistaken for other neuromuscular or metabolic disorders.
The commercial market has four layers:
| Market layer |
Commercial relevance |
| Diagnosed patients |
The immediate treated population |
| Undiagnosed patients |
Expansion opportunity through neurologist education and genetic testing |
| Previously treated patients |
Patients switching from off-label acetazolamide or other carbonic anhydrase inhibitors |
| International patients |
Potential licensing and distributor markets outside the United States |
The primary limitation is disease prevalence. The principal expansion opportunity is diagnosis. A small increase in diagnosed and treated patients can materially affect revenue because Keveyis is a chronic specialty product with high annual pricing.
What is the FDA regulatory status of Keveyis?
The FDA approved Keveyis on August 7, 2015, under the 505(b)(1) new drug application pathway. The approved indication covers primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants (FDA, 2015).
| Regulatory event |
Date |
| FDA approval of Keveyis |
August 7, 2015 |
| Initial approved population |
Adults and adolescents age 12 and older |
| Dosage form |
50 mg tablet |
| Orphan indication |
Primary periodic paralysis |
| Regulatory category |
New drug application |
| Current commercial owner |
Xeris Biopharma |
The approval relied on clinical evidence showing reductions in attack frequency and disease burden. Because the product treats a rare disorder, the label and commercial strategy depend heavily on specialist diagnosis, neuromuscular centers, patient support services, and reimbursement assistance.
When does dichlorphenamide lose exclusivity?
The key statutory orphan-drug exclusivity period began on the date of FDA approval and generally ran for seven years, subject to the scope of the orphan indication and applicable regulatory rules. For Keveyis, the initial seven-year period would have extended to August 7, 2022, assuming no extension altered the period.
Orphan exclusivity does not prevent all future competition. It prevents the FDA from approving the same drug for the same orphan indication during the protected period, subject to statutory exceptions. It does not automatically block:
- A generic applicant challenging patents through Paragraph IV;
- A product approved for a different indication;
- A different drug with a similar clinical mechanism;
- Compounded products in limited circumstances;
- International competitors operating outside the FDA framework.
After orphan exclusivity expires, patent protection and regulatory exclusivity become the main barriers to generic entry. The commercial importance of those protections depends on the patents listed in the Orange Book, the validity of the claims, the scope of any settlement, and the willingness of generic manufacturers to invest in a small-volume market.
What patents protect dichlorphenamide and Keveyis?
Keveyis is protected primarily through product, formulation, and method-of-use patent rights rather than through the novelty of dichlorphenamide as a chemical entity. Dichlorphenamide itself is an older carbonic anhydrase inhibitor, which limits the value of composition-of-matter protection for the active ingredient.
The relevant protection categories include:
- Drug product patents covering the approved tablet.
- Formulation patents covering dosage strength, excipients, stability, or administration.
- Method-of-use patents covering treatment of periodic paralysis.
- Regulatory exclusivity covering the approved orphan indication.
- Trade-secret and operational protection involving manufacturing, quality control, and specialty distribution.
Public company disclosures and FDA records should be reviewed together because an Orange Book patent listing may cover only a defined claim set. A listed patent does not establish validity or enforceability. It gives the NDA holder a basis to notify an ANDA applicant and potentially bring an infringement action.
How strong is the dichlorphenamide patent estate?
The estate is commercially meaningful but structurally weaker than the estate of a recently discovered small-molecule drug with unexpired composition-of-matter rights. Its strength depends on three factors:
- Whether later-expiring claims cover the approved product or an unavoidable method of use;
- Whether a generic can design around formulation or administration claims;
- Whether the cost of a Paragraph IV challenge is justified by the size of the remaining market.
The active ingredient's age increases the likelihood that generic manufacturers can source or synthesize it. The main barriers are therefore regulatory filing cost, limited market size, patent litigation risk, and the need to establish commercial distribution in a rare-disease market.
Are there Paragraph IV challenges or generic competitors?
No broadly commercialized U.S. generic equivalent had displaced Keveyis in the public market through the latest company and FDA disclosures reviewed for this analysis. The absence of a marketed generic does not mean generic risk is absent. An ANDA applicant can challenge listed patents before launching, and a small specialty product can attract a generic entrant if expected pricing and market share support the litigation and launch costs.
Potential generic entry paths include:
| Entry path |
Effect on Xeris |
| Authorized generic or licensed generic |
Controlled erosion with possible royalty or supply economics |
| First-filer Paragraph IV launch |
Rapid price and volume pressure |
| Multiple generic entrants |
Severe net-price compression |
| Single generic entrant |
Moderate to high erosion, depending on substitution |
| Compounded dichlorphenamide |
Localized pricing and access pressure |
| Alternative branded therapy |
Slower share loss but greater payer leverage |
For a rare disease product, one generic entrant can have a disproportionate impact because the total patient pool is limited. A generic does not need broad primary-care penetration to reduce branded utilization. It can target the same neurology centers and payer channels used by the branded product.
How does Xeris make money from dichlorphenamide?
Xeris acquired Strongbridge Biopharma in 2021 in a transaction valued at approximately $180 million, bringing Keveyis into Xeris's commercial portfolio (Xeris Biopharma, 2021). The acquisition expanded Xeris's presence in rare diseases and added an established commercial product to its platform.
Xeris reports company-level revenue, product revenue, and operating expenses, but product-level disclosure for Keveyis is not consistently sufficient to reconstruct a complete standalone income statement. The financial trajectory should therefore be evaluated through the following indicators:
- Net product revenue;
- Prescriptions and treated patient count;
- Gross-to-net deductions;
- Reimbursement approval rates;
- Patient support program costs;
- Sales and marketing expense;
- Manufacturing and supply costs;
- Cash generation after portfolio overhead.
What drives Keveyis revenue?
Keveyis revenue is driven by treatment duration and annual price per patient rather than by high prescription turnover. The key commercial variables are:
- Diagnosis growth among patients with unexplained episodic weakness.
- Conversion from off-label acetazolamide or related therapy.
- Persistence after initiation.
- Payer approval and prior-authorization success.
- Dose intensity and tablet utilization.
- Price increases, subject to payer and political constraints.
- Patient assistance and copay support.
The product has a recurring-revenue model. A patient who remains on treatment can generate revenue over multiple years, but the small population creates concentration risk. A modest number of discontinuations, payer exclusions, or treatment switches can affect annual results.
What is the financial trajectory of the drug and its owner?
Keveyis became part of Xeris's broader commercial portfolio after the Strongbridge acquisition. Xeris also markets other specialty products, including Gvoke and Recorlev, so consolidated financial statements do not isolate Keveyis's full contribution in every period.
The financial trajectory has three stages:
2015 to 2021: orphan-product commercialization
The product moved from regulatory approval into specialist commercialization. Revenue growth depended on creating awareness of periodic paralysis and establishing reimbursement pathways. The market remained constrained by low diagnosis rates.
2021 onward: integration into Xeris
Xeris acquired Strongbridge and inherited Keveyis's commercial infrastructure, patient services, and neuromuscular-market relationships. The product contributed to a more diversified rare-disease portfolio, but the acquisition also introduced integration and portfolio-allocation considerations.
Mature commercial phase
The mature phase is likely to show slower patient growth and greater dependence on pricing, persistence, and market protection. The strongest operating outcome would combine stable reimbursement with continued diagnosis expansion. The weakest outcome would combine orphan-exclusivity expiration, generic filing activity, payer restrictions, and declining net price.
Xeris's consolidated revenue increased materially after the Strongbridge transaction, but that increase cannot be attributed exclusively to Keveyis. Investors should avoid using total Xeris revenue as a direct proxy for dichlorphenamide demand.
What licensing deals affect dichlorphenamide?
The principal transaction affecting Keveyis was Xeris's acquisition of Strongbridge Biopharma in 2021. The transaction transferred the commercial asset within the corporate group rather than creating a conventional regional license.
International rights, distribution arrangements, and third-party commercialization terms should be evaluated separately from U.S. ownership. A regional license could create upfront, milestone, royalty, or supply revenue, but public company reporting must be consulted for jurisdiction-specific terms. The U.S. market remains the central commercial reference point because the product's regulatory approval and established specialist infrastructure are concentrated there.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate. Dichlorphenamide is a small molecule with an established chemical history, so the active ingredient is not inherently difficult to manufacture. Barriers arise from:
- Pharmaceutical-grade active-ingredient sourcing;
- Tablet uniformity and stability;
- Quality-system validation;
- FDA inspection readiness;
- Small production volumes;
- Supply-chain economics;
- Specialized distribution and patient support.
The low-volume nature of the market can discourage manufacturers from entering even when the chemistry is straightforward. A generic company must maintain supply reliability while competing for a limited number of treated patients. That economics can delay entry, but it does not eliminate it.
How does dichlorphenamide compare with acetazolamide and other treatments?
| Treatment |
Regulatory position |
Typical market role |
Competitive effect on Keveyis |
| Dichlorphenamide |
FDA-approved for primary periodic paralysis |
Branded chronic therapy |
Benchmark treatment |
| Acetazolamide |
Older carbonic anhydrase inhibitor; commonly used off label |
Lower-cost alternative |
Limits pricing power and supports switching risk |
| Potassium supplementation |
Supportive treatment in selected hypokalemic patients |
Adjunct or episode management |
Does not fully substitute for preventive therapy |
| Thiazide-related therapy |
Used selectively in some phenotypes |
Physician-directed alternative |
Can reduce addressable demand |
| Acute attack management |
Symptom or episode treatment |
Not equivalent to preventive therapy |
Limited direct substitution |
The most important competitive threat is often not a rival branded drug. It is continued use of lower-cost off-label therapy, especially when payers require step therapy or when patients experience adequate control with older medicines.
What generic launch risks exist?
Generic launch risk is moderate over the near term and rises as later patent barriers expire or are invalidated. The risk profile is asymmetric:
- Before an ANDA filing, the risk is mainly patent and regulatory monitoring.
- After a Paragraph IV notice, litigation can delay approval but may also confirm that a commercial challenger is active.
- After patent settlement, launch timing becomes contract-dependent.
- After first generic entry, net pricing can fall quickly because the treated population is concentrated and substitution is relatively easy.
Xeris's defense strategy may include patent litigation, settlement negotiations, lifecycle management, patient-service differentiation, and contracting with specialty pharmacies. The commercial value of these strategies depends on whether patients and prescribers view the branded product as materially different from a generic tablet.
What is the overall investment and commercial outlook?
Dichlorphenamide is a durable niche product with attractive orphan-drug economics but limited volume expansion. Its value rests on chronic use, specialized diagnosis, and a lack of broadly equivalent FDA-approved alternatives. Its weaknesses are the old active ingredient, the expiration of initial orphan exclusivity, potential generic substitution, and limited transparency around standalone product profitability.
The most relevant valuation questions are:
- How many treated patients does Keveyis support?
- What is the annual net revenue per patient after rebates and assistance?
- How much revenue is exposed to generic entry?
- Are later-expiring patents enforceable and difficult to design around?
- How much of Xeris's neuromuscular infrastructure is allocated to Keveyis?
- Can diagnosis growth offset price and exclusivity pressure?
Key Takeaways
- Dichlorphenamide is an FDA-approved orphan drug for primary periodic paralysis.
- Keveyis is commercialized by Xeris Biopharma following its 2021 acquisition of Strongbridge.
- The initial seven-year orphan exclusivity period began August 7, 2015 and generally ended August 7, 2022.
- The active ingredient is old, so the principal protection is expected to come from product, formulation, method-of-use, patent, and commercial barriers rather than new chemical entity protection.
- The market has high revenue per patient but a small treated population.
- Diagnosis expansion and long-term persistence are the main growth drivers.
- Off-label acetazolamide is the most important practical competitive alternative.
- Generic risk is manageable before filing activity but can become material after the first approved ANDA.
- Xeris's consolidated financial results do not provide a complete standalone Keveyis profit-and-loss statement.
- The product remains commercially valuable, but its long-term trajectory is more likely to be a stable specialty franchise than a high-volume growth asset.
Frequently Asked Questions
Is dichlorphenamide the same as Keveyis?
Yes. Dichlorphenamide is the active ingredient, and Keveyis is the U.S. branded product name.
Is dichlorphenamide a generic drug?
The active ingredient is an older small molecule, but Keveyis is the branded FDA-approved product for primary periodic paralysis. A separately approved generic version would require an ANDA and would remain subject to applicable patents and regulatory requirements.
Can acetazolamide replace dichlorphenamide?
Acetazolamide is used off label in periodic paralysis and may be selected because of its lower cost or physician experience. It is not the same FDA-approved product indication as Keveyis and may not provide equivalent control for every patient.
Does dichlorphenamide have biosimilar risk?
No. Dichlorphenamide is a small molecule, not a biologic. Its relevant competitive risk is generic substitution through the ANDA pathway, not biosimilar approval.
What is the main commercial risk for Keveyis?
The main risk is erosion of branded demand through generic entry, payer pressure, or substitution with lower-cost off-label carbonic anhydrase inhibitors after orphan exclusivity and patent protection weaken.
References
U.S. Food and Drug Administration. (2015). FDA approves treatment for periodic paralysis. https://www.fda.gov
U.S. Food and Drug Administration. (2023). Keveyis (dichlorphenamide) prescribing information. https://www.accessdata.fda.gov
Xeris Biopharma Holdings, Inc. (2021). Xeris Biopharma to acquire Strongbridge Biopharma plc. https://investors.xerispharma.com
Xeris Biopharma Holdings, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov
U.S. Securities and Exchange Commission. (2021). Strongbridge Biopharma plc merger materials. https://www.sec.gov
